Latest News for: t1d
Edit
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases (T1D Fund A Breakthrough T1D Venture LLC)
Public Technologies 07 Oct 2026
Launched in 2016 as a wholly owned subsidiary of Breakthrough T1D, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through investments.
Edit
Breakthrough T1D Strengthens Cybersecurity and IT Resilience with Managed IT Services from Canon and Supra ITS
Nasdaq Globe Newswire 06 Oct 2026
Edit
Breakthrough T1D says it fired three board members of the T1D Fund to protect the ...
Wall Street Journal 02 Oct 2026
Breakthrough T1D says it fired three board members of the T1D Fund to protect the interest of donors; those dismissed say Breakthrough crushed the fund’s independence ... .
Edit
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Nasdaq Globe Newswire 01 Oct 2026
Edit
Morgan Citizen
01 Oct 2026
Breakthrough T1D Walks Bring Communities Together and Raise Funds for Type 1 Diabetes Research
1, 2026 /PRNewswire/ -- Breakthrough T1D, formerly ...
Edit
Killeen Daily Herald
28 Sep 2026
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a ...
Edit
Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes
Business Wire 23 Sep 2026
Edit
Killeen Daily Herald
19 Sep 2026
Orange Biomed Joins T1D Families at Camp to Community High Country in North Carolina
Edit
Office Practicum User Conference Leads to Life-Changing T1D Intervention
PR Newswire 14 Jul 2026
His keynote explored the rapidly evolving landscape of Type 1 diabetes (T1D) screening and intervention in children ... screen children for the autoantibodies associated with Type 1 diabetes (T1D).
Edit
Hastings Tribune
07 Jul 2026
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, ...
Edit
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes (Form 8-K) (SAB Biotherapeutics Inc)
Public Technologies 07 Jul 2026
Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes. MIAMI, July 7, 2026 - Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc.
- 1